Pyruvate kinase activators in hereditary haemolytic anaemias: current evidence and clinical potential

The authors investigate the potential of pyruvate kinase activators as a therapeutic option for hereditary haemolytic anaemias, which are prevalent genetic disorders with limited treatment options. They highlight recent evidence showing that these activators can enhance glycolysis, improve ATP production, and alleviate symptoms in various haemolytic conditions, while also maintaining a favorable safety profile. The paper emphasizes the need for ongoing research to explore additional applications of pyruvate kinase activators in treating these disorders.